Table 1.
Inhibitory activity of synthesized isatin derivatives against DNA viruses
| S. no. | Compounds | Human embryonic cell culture (HEL) ECa50 (μM) | Crandell–Rees feline kidney cell culture (CRFK) | Human embryonic cell culture (HEL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytomegalovirus | Herpes simplex virus-1 (KOS) | Herpes simplex virus-2 (G) | Vaccinia virus | Vesicular stomatitis virus | Herpes simplex virus-1TK-KOS ACVr | Feline corona virus | Feline herpes virus | Varicella-zoster virus (VZV) | ||||
| AD-169 strain | Davis strain | TK + VZV strain | TK-VZV strain | |||||||||
| 1 | 4a | 12 ± 3.5 | 15 ± 0.4 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >4 | 7.4 |
| 2 | 4b | 16 ± 3.7 | 11.32 ± 0.08 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| 3 | 4c | >20 | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 4 | 4d | >20 | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 | >20 |
| 5 | 4e | >20 | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 | >20 |
| 6 | 4f | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >100 | >100 | >20 | >20 |
| 7 | 4g | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 |
| 8 | 6a | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 | >100 |
| 9 | 6b | >20 | >20 | >100 | >100 | >100 | >100 | >100 | >100 | 19.7 | >20 | >20 |
| 10 | 6c | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | 55.1 | >100 | >100 |
| 11 | 6d | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 | >20 |
| 12 | 6e | >20 | >20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >20 | >20 |
| 13 | Ganciclovir | 8.1 ± 0.2 | 5.5 ± 2.36 | 0.02 | 0.01 | >100 | >100 | 4 | >100 | 1.4 | – | – |
| 14 | Cidofovir | 1.0 ± 0.05 | 0.78 ± 0.49 | 2 | 1 | 22 | >250 | 0.9 | – | – | – | – |
| 15 | Brivudin | – | – | 0.04 | 112 | 4 | >250 | 50 | – | – | 2.1 | 143 |
| 16 | Acyclovir | – | – | 0.4 | 0.2 | >250 | >250 | 22 | – | – | 0.019 | 104.5 |
| 17 | HHA (μg ml−1) | – | – | – | – | – | – | – | 4.2 | 11.0 | – | – |
| 18 | UDA (μg ml−1) | – | – | – | – | – | – | – | 1.6 | 1.2 | – | – |
“–” not performed
aRequired to reduce virus-induced cytopathogenicity by 50 %